Medicus Pharma Ltd. (MDCX)
| Market Cap | 45.16M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.75M |
| Shares Out | 22.03M |
| EPS (ttm) | -2.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 370,909 |
| Open | 2.010 |
| Previous Close | 1.920 |
| Day's Range | 1.930 - 2.100 |
| 52-Week Range | 1.675 - 8.940 |
| Beta | -1.98 |
| Analysts | Strong Buy |
| Price Target | 23.50 (+1,046.34%) |
| Earnings Date | Nov 14, 2025 |
About MDCX
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for MDCX stock is "Strong Buy." The 12-month stock price target is $23.5, which is an increase of 1,046.34% from the latest price.
News
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA / ACCESS Newswire / December 5, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"),...
Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President
Carolyn Bonner Succeeds James ('Jim') Quinlan Who Has Resigned for Health Reasons After Taking Medical Leave in September 2025 PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 1, 2025 / Medicus...
Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers
November is Men's Health Awareness Month, a time to spotlight the latest medical breakthroughs that are transforming how we detect and treat cancer in men.
Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access...
Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights
Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire...
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM PHILADELPHIA, PA / ACCESS Newswire / No...
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) le...
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) le...
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
CLEVELAND CLINIC ABU DHABI (CCAD) IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PA / ACCESS Newswire / October 22, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the...
The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets
BRISTOL, TN / ACCESS Newswire / October 14, 2025 / Most biotech stories collapse on a single product failure. Medicus Pharma Ltd (NASDAQ:MDCX) built three distinct shots at blockbuster markets.
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (...
Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSION The Summit theme "unlocking the $1 Trillion Wealth transfer in Dubai" PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 7,...
Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject
The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of the skin using dissolvable Doxorubicin-containing Microneedle arrays (D-MN...
Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)
Dallas, Texas--(Newsfile Corp. - September 24, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX): Stonegate Capital Partners initiates their coverage on Medicus Pharma Ltd.
Medicus Pharma Ltd. To Present at Brookline Capital Markets
The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix, ...
Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing
The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV r...
Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
CLEVELAND CLINIC ABU DHABI (CCAD) HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September 8, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus"...
Medicus Pharma Ltd. Completes Acquisition of Antev Limited
Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 b...
Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights
US Food and Drug Administration (FDA) has accepted the company's Type C meeting request and SKNJCT-003 Phase 2 study has randomized more than 75% of patients Philadelphia, Pennsylvania--(Newsfile Corp...
Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines
The MOU intends to combine proprietary mRNA vaccine platform of HelixNano with proprietary Microneedle array (MNA) delivery platform of Medicus. Philadelphia, Pennsylvania--(Newsfile Corp. - August 4,...
Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders
The Company added Congresswoman Cathy McMorris Rodgers & Ajay Raju, Esq. to the Board of Directors.
Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025
Executive Chairman & CEO of the Company to Participate in a Fireside Chat Philadelphia, Pennsylvania--(Newsfile Corp. - July 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company")...
Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)
The Company's aim is to seek FDA consent to fast track the Clinical Development Program to treat Basal Cell Carcinoma (BCC) of the skin using Dissolvable Doxorubicin-containing Microneedle Arrays (D-M...
Medicus Pharma: High-Risk But Higher Reward For Their Potential Breakthrough Skin Cancer Treatment
Medicus Pharma offers high-risk, high-reward potential with its novel SkinJect patch for basal cell carcinoma and recent Antev acquisition expanding its pipeline. Strong insider/institutional backing ...
Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK
Antev Shareholders to Receive Aggregate ~17% Equity Stake in Medicus plus US$65 Million in Contingent Payments Philadelphia, Pennsylvania--(Newsfile Corp. - June 30, 2025) - Medicus Pharma Ltd. (NASDA...